The Truth Behind the GLP-1 Price Announcements

The federal government recently announced new agreements intended to lower the cost of certain GLP-1 medications, but these reductions primarily apply to Medicare and Medicaid beneficiaries and only through specific government channels. For most people with employer-sponsored or private insurance, these changes will not translate into lower prices in the near term: commercial plans are not included, eligibility remains tied to strict diabetes or obesity criteria, and off-label use for longevity or metabolic optimization is still not covered. 

Because of these limitations, many patients continue to find Sur’s cash-pay tirzepatide program the most reliable and cost-effective option—we offer competitive pricing across every dose, predictable monthly costs, and clinical support for personalized, off-label use when medically appropriate. If you’re considering GLP-1 therapy or want help comparing options, we’re here to guide you toward the most accessible and consistent path forward.